Pathology Grand Rounds October 2023- Sponsored by PathSoc & the Jean Shanks Foundation скачать в хорошем качестве

Pathology Grand Rounds October 2023- Sponsored by PathSoc & the Jean Shanks Foundation

SPEAKER- Prof. Christian Ottensmeier- University of Liverpool "Activating tumour reactive T cells for cancer immunotherapy? There may be a problem" Christian Ottensmeier MD PhD FRCP is a medical oncologist who trained at the Westfälische Wilhelms-University Münster, Germany, followed by a fellowship at the Dana Farber Cancer Institute in Boston, MA. He completed his PhD in molecular immunology in Southampton; he was appointed to a chair in Experimental Cancer Medicine there in 2007 and in 2019 to an Associate Professorship at the La Jolla Institute for Immunology, CA, USA. mHe joined the University of Liverpool, the Liverpool Head and Neck Center, and Clatterbridge Cancer Centre as a Professor of Immuno-Oncology in August 2020. Since January 2022 he serves as the Director of Clinical Research at Clatterbridge Cancer Center. He leads an early phase portfolio of trials to deliver more effective immunotherapy with a focus on head and neck cancer and lung cancer. His laboratory studies how best to induce tumour-antigen specific immunity through vaccination and how to overcome immune suppressive features of the tumour microenvironment. He contributes to the editorial boards for the Journal of Translational Immunology and the newly founded open source BSI Journal “Immunotherapy Advances”. ABSTRACT: "Activating tumour reactive T cells for cancer immunotherapy? there may be a problem " Immunotherapy has revolutionised cancer treatment. The key drugs, anti-PD1 or anti-PDL1 antibodies release pre-existing T cells that recognise tumour antigens. Where such T cells are lacking in number anti-cancer vaccination may train new tumour reactive T cells. However while T cells in the tumour microenvironment can have an effector function, there are also significant populations of T cells that have a regulatory phenotype. Vaccination may thus activate effector and inhibitory T cells at the same time. Which antigens drive regulatory over effector T cells is currently unclear but this may profoundly affect the outcome of anti-tumour vaccination, particularly as checkpoint inhibitors are likely to amplify this effect.on.